MK4830 KN001- A Phase 1 Open Label, Multi-Arm, Multicenter Study of MK-4830 as Monotherapy and in Combination with Pembrolizumab for Participants with Advanced Solid Tumors

February 24, 2019
https://clinicaltrials.gov/ct2/show/NCT03564691
Cancer - Melanoma, Cancer - Sarcoma, Cancer - Breast, Cancer - Head and Neck, Cancer - Lymphoma, Solid Tumors, Cancer - Colon Rectal
Principal Investigator: Ding Wang, MD
advanced cancer, lymphoma, non-Hodgkin's lymphoma, melanoma advanced, breast cancer, head and neck cancer, Hodgkin's disease, Solid tumors, Pembrolizumab
Accepting Participants